Abstract: SA-PO0862
Real-World Use and Clinical Outcomes with Sparsentan in the United Kingdom (UK) and Germany
Session Information
- Glomerular Diseases: Management, Evolving Strategies, and Practice-Changing Advances
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Csomor, Philipp, CSL, Glattbrugg, Switzerland
- Cheung, Chee Kay, University of Leicester, Leicester, England, United Kingdom
- Lafave, Jennifer, Spherix Global Insights, Exton, Pennsylvania, United States
- McCarthy, Kari, Spherix Global Insights, Exton, Pennsylvania, United States
- Santos, Lucy, CSL, Glattbrugg, Switzerland
Background
Sparsentan (SPAR), a dual endothelin angiotensin receptor antagonist, is approved for the treatment of patients with primary immunoglobulin A nephropathy (IgAN). In the PROTECT study, SPAR resulted in significant proteinuria reduction and kidney function preservation compared with maximum labeled dose irbesartan in adults with IgAN. The present analysis describes real-world prescribing patterns and outcomes with SPAR in the UK and Germany.
Methods
Between January 7–29, 2026, physicians from Germany and the UK completed a patient chart audit and questionnaire on IgAN management. Physicians were required to have ≥50 patients (pts) with chronic kidney disease Stage 1–4 in their care, including ≥4 non-dialysis IgAN pts. Charts were from non-dialysis IgAN pts aged ≥13 years, with an estimated glomerular filtration rate (eGFR) of ≥15 mL/min/1.73 m2.
Results
In total, 129 physicians completed the questionnaire and chart audits for 225 IgAN pts. Of the pts audited, 30 (13%) were receiving SPAR. Clinical characteristics of the 30 SPAR pts are provided in Table 1. At the time of analysis, pts had been receiving SPAR for an average of 4.7 months (range: 1–14 months). Mean proteinuria was 2.6 g/day (or equivalent) at treatment initiation vs 1.5 g/day at the most recent clinic visit for pts with available data at both time points (n=23). Mean eGFR was 45.6 mL/min/1.73 m2 at treatment initiation (n=28) vs 45.7 mL/min/1.73 m2 at the most recent visit (n=30). Two pts chose to discontinue SPAR citing continued disease progression. Most pts initiated SPAR despite background sodium–glucose cotransporter 2 inhibitor use due to inadequate proteinuria control, worsening kidney function, or biopsy findings; 63% had inflammatory features. 77% of physicians believed their pts were fully adherent to SPAR, and 67% ranked it as an “extremely effective” treatment option.
Conclusion
Pts with IgAN receiving SPAR experienced clinically relevant reductions in UPCR and stabilized eGFR. Real-world experience indicates that SPAR is an effective treatment option with good adherence in clinical practice.
Funding
- Commercial Support – This analysis was funded by CSL and performed in partnership with Spherix Global Insights. The collation of data used for this study was independently sponsored and conducted by Spherix Global Insights.